A Phase 2 interventional study of Exemestane and Abiraterone acetate + Prednisone/ Prednisolone + Exemestane in Metastatic ER+ Her2- Breast Cancer and Postmenopausal, sponsored by Janssen Research & Development, LLC. Completed at 85 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-11.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Breast Neoplasms by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Johnson & Johnson.
Among the 19 studies in Breast Neoplasms by Johnson & Johnson, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 2, and was the 13th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 19 studies in Breast Neoplasms by Johnson & Johnson is open now, in 2 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Australia
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 297 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 114 across the 18 interventional studies, 500 across the 1 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Breast Neoplasms by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04829604Ambrx, Inc.ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Breast Neoplasms by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.
This is a randomized (study drug assigned by chance), open-label (all participants will know the identity of the assigned study drug) study divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. The treatment phase will comprise a series of 28-day cycles with continuous study treatment until breast cancer progression, when an end-of-treatment visit will be completed before the follow-up phase begins. The duration of participation in the study for an individual patient may be up to approximately 7 years, including follow-up evaluations. Patients will be evaluated for the safety and effectiveness of study treatments. During the treatment phase, patients will take the following study drugs by mouth once daily: abiraterone acetate, 1 g/day, as four 250-mg tablets, on an empty stomach, and patients must not eat for at least 1 hour after abiraterone acetate; prednisone (prednisolone when prednisone is not available), 5 mg/day; and exemestane, 25 mg/day, as a single tablet. The treatment phase will consist of a series of 28-day cycles with continuous study treatment until breast cancer progression. At the planned interim analysis, the Data Review Committee has recommended that further randomization to the abiraterone acetate alone group be stopped and that the study is to be continued otherwise.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
Drug: Abiraterone acetate + Prednisone or Prednisolone
Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane
Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
Drug: Exemestane
Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
Drug pages: Abiraterone Acetate · Prednisone · Prednisolone · Exemestane
Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
Progression-Free Survival (PFS)
Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.
Time frame: Approximately 2 years
Overall Survival (OS)
OS was calculated as the time from randomization to death from any cause.
Time frame: Approximately 3 years
Overall Response Rate (ORR)
Overall response rate was defined as the percentage of participants with measurable disease achieving a best overall response of either complete response (CR) or partial response (PR) based on RECIST. CR: disappearance of all target lesions and non-target lesions. PR: at least a 30 percent (%) decrease in the sum of longest diameter (LD) of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Time frame: Approximately 2 years
Clinical Benefit Rate
Clinical benefit rate was defined as the percentage of participants with measurable disease achieving a best overall response of a CR, PR, or stable disease (SD) for at least 6 months based on RECIST. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.
Time frame: Approximately 2 years
Duration of Response
Duration of objective response was measured from the first time that the CR or PR was achieved to the first observation of disease progression (either radiographic or clinical) based on the RECIST criteria.
Time frame: Approximately 2 years
Change From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment
Change from baseline in serum endocrine biomarkers (estradiol and estrone) was summarized by treatment at end of treatment.
Time frame: Baseline and End of treatment (approximately 2 years)
Change From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment
Change from baseline in serum endocrine biomarkers (Progesterone and Testosterone) was summarized by treatment at end of treatment.
Time frame: Baseline and End of treatment (approximately 2 years)
| Milestone | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Started | 102 | 89 | 106 |
| Treated | 102 | 87 | 104 |
| Completed | 25 | 26 | 30 |
| Not completed | 77 | 63 | 76 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 10 | 9 |
| Withdrew: Other | 67 | 52 | 67 |
Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.
| Months | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Progression-Free Survival (PFS) | 3.68 (1.94 to 5.26) | 3.65 (2.73 to 5.59) | 4.47 (3.68 to 5.59) |
OS was calculated as the time from randomization to death from any cause.
| Months | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | 26.41 (23.49 to NA) | NA (23.79 to NA) |
Overall response rate was defined as the percentage of participants with measurable disease achieving a best overall response of either complete response (CR) or partial response (PR) based on RECIST. CR: disappearance of all target lesions and non-target lesions. PR: at least a 30 percent (%) decrease in the sum of longest diameter (LD) of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
| Percentage of participants | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Overall Response Rate (ORR) | 6.3 | 5.8 | 12.1 |
Clinical benefit rate was defined as the percentage of participants with measurable disease achieving a best overall response of a CR, PR, or stable disease (SD) for at least 6 months based on RECIST. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.
| Percentage of participants | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Clinical Benefit Rate | 12.7 | 9.6 | 22.7 |
Duration of objective response was measured from the first time that the CR or PR was achieved to the first observation of disease progression (either radiographic or clinical) based on the RECIST criteria.
| months | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Duration of Response | 6.47 (NA to NA) | 4.86 (4.63 to NA) | 6.93 (4.57 to NA) |
Change from baseline in serum endocrine biomarkers (estradiol and estrone) was summarized by treatment at end of treatment.
| Picomoles Per Liter (Pmol/L) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Estradiol | 1.53 ± 27.643 | -3.35 ± 13.634 | -1.04 ± 20.146 |
| Estrone | -34.20 ± 83.770 | -28.09 ± 47.779 | -30.60 ± 42.385 |
Change from baseline in serum endocrine biomarkers (Progesterone and Testosterone) was summarized by treatment at end of treatment.
| Nanomoles Per Liter (nmol/L) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| Progesterone | -4.80 ± 18.268 | 8.98 ± 15.113 | 12.34 ± 16.967 |
| Testosterone | -0.09 ± 0.416 | -0.51 ± 0.459 | -0.48 ± 0.323 |
Collected over Approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exemestane | 1/102 (1%) | 12/102 (11.8%) | 79/102 (77.5%) |
| Abiraterone Acetate + Prednisone | 0/87 (0%) | 18/87 (20.7%) | 76/87 (87.4%) |
| Abiraterone Acetate + Exemestane + Prednisone | 2/104 (1.9%) | 28/104 (26.9%) | 84/104 (80.8%) |
| Event | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 1/102 | 3/87 | 0/104 |
| Abdominal PainGastrointestinal disorders | 0/102 | 0/87 | 3/104 |
| VomitingGastrointestinal disorders | 0/102 | 0/87 | 3/104 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/102 | 0/87 | 3/104 |
| Back PainMusculoskeletal and connective tissue disorders | 0/102 | 2/87 | 0/104 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 0/102 | 2/87 | 0/104 |
| Pathological FractureMusculoskeletal and connective tissue disorders | 0/102 | 2/87 | 0/104 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 1/102 | 1/87 | 2/104 |
| Atrial FibrillationCardiac disorders | 0/102 | 1/87 | 1/104 |
| Crohn's DiseaseGastrointestinal disorders | 0/102 | 1/87 | 0/104 |
| Event | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone |
|---|---|---|---|
| FatigueGeneral disorders | 27/102 | 24/87 | 21/104 |
| NauseaGastrointestinal disorders | 18/102 | 21/87 | 22/104 |
| HypokalaemiaMetabolism and nutrition disorders | 4/102 | 19/87 | 14/104 |
| VomitingGastrointestinal disorders | 7/102 | 12/87 | 19/104 |
| Bone PainMusculoskeletal and connective tissue disorders | 18/102 | 13/87 | 13/104 |
| Back PainMusculoskeletal and connective tissue disorders | 12/102 | 15/87 | 17/104 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/102 | 8/87 | 11/104 |
| Decreased AppetiteMetabolism and nutrition disorders | 11/102 | 13/87 | 17/104 |
| ConstipationGastrointestinal disorders | 9/102 | 14/87 | 15/104 |
| Hot FlushVascular disorders | 14/102 | 14/87 | 9/104 |
| Age, Continuous(years) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone | Total |
|---|---|---|---|---|
| Mean | 61.9 ± 8.55 | 63.1 ± 9.17 | 63.8 ± 10.91 | 62.9 ± 9.63 |
| Sex: Female, Male(Participants) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone | Total |
|---|---|---|---|---|
| Female | 102 | 89 | 106 | 297 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 3 |
| Not Hispanic or Latino | 84 | 72 | 95 | 251 |
| Unknown or Not Reported | 18 | 15 | 10 | 43 |
| Race (NIH/OMB)(Participants) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 5 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 92 | 76 | 96 | 264 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 9 | 11 | 4 | 24 |
| Region of Enrollment(Participants) | Exemestane | Abiraterone Acetate + Prednisone | Abiraterone Acetate + Exemestane + Prednisone | Total |
|---|---|---|---|---|
| USA | 9 | 11 | 8 | 28 |
| Belgium | 18 | 21 | 21 | 60 |
| France | 17 | 13 | 11 | 41 |
| Spain | 11 | 7 | 12 | 30 |
| United Kingdom | 7 | 12 | 11 | 30 |
| Italy | 0 | 1 | 4 | 5 |
| Korea, Republic Of | 1 | 0 | 5 | 6 |
| Netherlands | 8 | 5 | 8 | 21 |
| Russia | 20 | 12 | 19 | 51 |
| Ukraine | 11 | 7 | 7 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2011 to primary completion in Jul 2014, 35 months.
Results were first posted in Jul 2018, 3 years 11 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 35 months is close to that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abiraterone Acetate · Prednisone · Prednisolone · Exemestane
Janssen Research & Development, LLC →